Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis.
BACKGROUND
Mobilized-peripheral blood hematopoietic stem cells (HSCs) have been used for transplantation, immunotherapy, and cardiovascular regenerative medicine. Agents used for HSC mobilization include G-CSF and the CXCR4 inhibitor AMD3100 (plerixafor). The HSCs cells mobilized by each agent may contain different subtypes and have different functions. To characterize mobilized HSCs used for clinical applications, microRNA (miRNA) profiling and gene expression profiling were used to compare AMD3100-mobilized CD133+ cells from 4 subjects, AMD3100 plus G-CSF-mobilized CD133+ cells from 4 subjects and G-CSF-mobilized CD34+ cells from 5 subjects. The HSCs were compared to peripheral blood leukocytes (PBLs) from 7 subjects.


RESULTS
Hierarchical clustering of miRNAs separated HSCs from PBLs. miRNAs up-regulated in all HSCs included hematopoiesis-associated miRNA; miR-126, miR-10a, miR-221 and miR-17-92 cluster. miRNAs up-regulated in PBLs included miR-142-3p, -218, -21, and -379. Hierarchical clustering analysis of miRNA expression separated the AMD3100-mobilized CD133+ cells from G-CSF-mobilized CD34+ cells. Gene expression analysis of the HSCs naturally segregated samples according to mobilization and isolation protocol and cell differentiation status.


CONCLUSIONS
HSCs and PBLs have unique miRNA and gene expression profiles. miRNA and gene expression microarrays maybe useful for assessing differences in HSCs.
Jin
Ping
P
Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA. pjin@cc.nih.gov
Wang
Ena
E
Ren
Jiaqiang
J
Childs
Richard
R
Shin
Jeong Won
JW
Khuu
Hanh
H
Marincola
Francesco M
FM
Stroncek
David F
DF
D015703:Antigens, CD / Q000378:metabolism; D018952:Antigens, CD34 / Q000378:metabolism; D001596:Benzylamines; D000080027:Cyclams; D018076:DNA, Complementary / Q000378:metabolism*; D004334:Drug Administration Schedule; D020869:Gene Expression Profiling; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism*; D006571:Heterocyclic Compounds / Q000008:administration & dosage; D006801:Humans; D018189:Immunomagnetic Separation; D007279:Injections, Subcutaneous; D007937:Leukapheresis; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D035683:MicroRNAs / Q000378:metabolism*; D012015:Reference Standards; D013997:Time Factors
D015703:Antigens, CD; D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D018076:DNA, Complementary; D006571:Heterocyclic Compounds; D035683:MicroRNAs; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor